Gan L, Wang W, Jiang J, Tian K, Liu W, Cao Z
Front Immunol. 2024; 15:1429836.
PMID: 39286246
PMC: 11402828.
DOI: 10.3389/fimmu.2024.1429836.
Hasani S, Khalaj-Kondori M, Safaei S, Amini M, Riazi-Tabrizi N, Maghsoudi M
Discov Oncol. 2024; 15(1):424.
PMID: 39256224
PMC: 11387580.
DOI: 10.1007/s12672-024-01312-6.
Rahman M, Hossain M, Islam S, Ahmed R, Majumder M, Dey S
BMC Mol Cell Biol. 2024; 25(1):4.
PMID: 38336617
PMC: 10858504.
DOI: 10.1186/s12860-024-00500-0.
Ngo H, Le H, Surh Y
J Cancer Prev. 2024; 28(4):131-142.
PMID: 38205365
PMC: 10774478.
DOI: 10.15430/JCP.2023.28.4.131.
Jones T, Espitia C, Chipollini J, Lee B, Wertheim J, Carew J
Cancer Res Commun. 2023; 3(2):245-257.
PMID: 36860653
PMC: 9973416.
DOI: 10.1158/2767-9764.CRC-22-0340.
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.
Paramasivan P, Kankia I, Langdon S, Deeni Y
Cancer Drug Resist. 2022; 2(3):490-515.
PMID: 35582567
PMC: 8992506.
DOI: 10.20517/cdr.2019.57.
The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation.
Matsuoka Y, Yoshida R, Kawahara K, Sakata J, Arita H, Nkashima H
Lab Invest. 2022; 102(8):896-907.
PMID: 35414650
PMC: 9309095.
DOI: 10.1038/s41374-022-00776-w.
Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling.
Jawa Y, Yadav P, Gupta S, Mathan S, Pandey J, Saxena A
Front Oncol. 2021; 11:676948.
PMID: 34490084
PMC: 8418074.
DOI: 10.3389/fonc.2021.676948.
p62 functions as a signal hub in metal carcinogenesis.
Zhang Z, Costa M
Semin Cancer Biol. 2021; 76:267-278.
PMID: 33894381
PMC: 9161642.
DOI: 10.1016/j.semcancer.2021.04.014.
c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
Tang Y, Hsiao J, Jiang S, Chang J, Chu P, Liu K
Theranostics. 2021; 11(11):5232-5247.
PMID: 33859744
PMC: 8039948.
DOI: 10.7150/thno.53417.
NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis.
Robertson H, Dinkova-Kostova A, Hayes J
Cancers (Basel). 2020; 12(12).
PMID: 33276631
PMC: 7761610.
DOI: 10.3390/cancers12123609.
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies.
Jaganjac M, Milkovic L, Sunjic S, Zarkovic N
Antioxidants (Basel). 2020; 9(11).
PMID: 33228209
PMC: 7699519.
DOI: 10.3390/antiox9111151.
Evaluation of the Epigenetic Demethylation of NRF2, a Master Transcription Factor for Antioxidant Enzymes, in Colorectal Cancer.
Taheri Z, Aghdaei H, Irani S, Modarressi M, Zahra N
Rep Biochem Mol Biol. 2020; 9(1):33-39.
PMID: 32821749
PMC: 7424424.
DOI: 10.29252/rbmb.9.1.33.
Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo.
Pasqual-Melo G, Nascimento T, Sanches L, Blegniski F, Bianchi J, Sagwal S
Cancers (Basel). 2020; 12(7).
PMID: 32708225
PMC: 7409328.
DOI: 10.3390/cancers12071993.
Pathogenesis and anti-proliferation mechanisms of Crocin in human gastric carcinoma cells.
Luo Y, Yu P, Zhao J, Guo Q, Fan B, Diao Y
Int J Clin Exp Pathol. 2020; 13(5):912-922.
PMID: 32509062
PMC: 7270694.
Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways.
Lee Y, Kim W, Bae J, Cho M, Lee S, Nam H
Ann Surg Treat Res. 2020; 98(4):159-167.
PMID: 32274363
PMC: 7118325.
DOI: 10.4174/astr.2020.98.4.159.
Radiosensitization of Head and Neck Squamous Cell Carcinoma (HNSCC) by a Podophyllotoxin.
Resendez A, Tailor D, Graves E, V Malhotra S
ACS Med Chem Lett. 2019; 10(9):1314-1321.
PMID: 31531203
PMC: 6746081.
DOI: 10.1021/acsmedchemlett.9b00270.
Impact and Relevance of the Unfolded Protein Response in HNSCC.
Pluquet O, Galmiche A
Int J Mol Sci. 2019; 20(11).
PMID: 31151143
PMC: 6601021.
DOI: 10.3390/ijms20112654.
Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
Huang H, Wu Y, Fu W, Wang X, Zhou L, Xu X
Int J Mol Med. 2019; 43(5):2044-2054.
PMID: 30896860
PMC: 6443340.
DOI: 10.3892/ijmm.2019.4134.
DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer.
Zhang Q, Zhang Z, Du H, Li S, Tu R, Jia Y
Cell Death Differ. 2019; 26(11):2300-2313.
PMID: 30778200
PMC: 6889501.
DOI: 10.1038/s41418-019-0303-z.